Ascendis Pharma A/S (NASDAQ:ASND) has been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $36.95.
A number of equities analysts recently commented on ASND shares. Wedbush reiterated an “outperform” rating and set a $10.71 price target (down previously from $65.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. Bank of America Corporation reiterated a “buy” rating and set a $36.00 price target (up previously from $34.00) on shares of Ascendis Pharma A/S in a report on Monday, September 25th. Credit Suisse Group reiterated an “outperform” rating and set a $50.00 price target (up previously from $30.00) on shares of Ascendis Pharma A/S in a report on Friday, September 22nd. TheStreet cut Ascendis Pharma A/S from a “c-” rating to a “d” rating in a report on Thursday, June 15th. Finally, Wells Fargo & Company reiterated a “buy” rating and set a $51.00 price target on shares of Ascendis Pharma A/S in a report on Friday, September 22nd.
Ascendis Pharma A/S (NASDAQ:ASND) traded up 1.536% during trading on Friday, hitting $36.695. The company had a trading volume of 44,313 shares. The stock’s market capitalization is $1.19 billion. Ascendis Pharma A/S has a one year low of $17.15 and a one year high of $42.00. The stock has a 50-day moving average of $32.97 and a 200-day moving average of $32.97.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Friday, August 18th. The biotechnology company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.24). Ascendis Pharma A/S had a negative return on equity of 67.76% and a negative net margin of 2,977.70%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.78 million. During the same quarter in the previous year, the business posted ($0.53) EPS. The company’s revenue for the quarter was down 61.4% on a year-over-year basis. On average, equities analysts anticipate that Ascendis Pharma A/S will post ($0.14) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/10/11/ascendis-pharma-as-asnd-receives-36-95-consensus-pt-from-analysts.html.
Several large investors have recently modified their holdings of ASND. Janus Henderson Group PLC bought a new stake in shares of Ascendis Pharma A/S during the second quarter worth approximately $15,403,000. EcoR1 Capital LLC boosted its holdings in shares of Ascendis Pharma A/S by 44.5% during the second quarter. EcoR1 Capital LLC now owns 1,482,600 shares of the biotechnology company’s stock worth $41,157,000 after acquiring an additional 456,900 shares during the period. OppenheimerFunds Inc. bought a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $8,334,000. Marshall Wace North America L.P. bought a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $5,022,000. Finally, MARSHALL WACE ASIA Ltd bought a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $5,022,000. Institutional investors own 64.00% of the company’s stock.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.